Dawid Lipski

Dr. Dawid Lipski


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Dorota FormanowiczDorota Formanowicz
Dorota Formanowicz
JKJacek Krawczyk
Jacek Krawczyk
BPBartlomiej Perek
Bartlomiej Perek
DLDawid Lipski
Dawid Lipski
ATAndrzej Tykarski
Andrzej Tykarski
While the use of statins in treating patients with atherosclerosis is an undisputed success, the questions regarding an optimal starting time for treatment and its strength remain open. We proposed in our earlier paper published in Int. J. Mol. Sci. (2019, 20) that the growth of intima-media thickness of the carotid artery follows an S-shape (i.e., logistic) curve. In our subsequent paper in PLoS ONE (2020, 15), we incorporated this feature into a logistic control-theoretic model of atherosclerosis progression and showed that some combinations of patient age and intima-media thickness are better suited than others to start treatment. In this study, we perform a new and comprehensive calibration of our logistic model using a recent clinical database. This allows us to propose a procedure for inferring an optimal age to start statin treatment for a particular group of patients. We argue that a decrease in the slope of the IMT logistic growth curve, induced by statin treatment, is most efficient where the curve is at its steepest, whereby the efficiency means lowering the future IMT levels. Using the procedure on an aggregate group of severely sick men, 38 years of age is observed to correlate with the steepest point of the logistic curve, and, thus, it is the preferred time to start statin treatment. We believe that detecting the logistic curve’s steepest fragment and commencing statin administration on that fragment are courses of action that agree with clinician intuition and may support decision-making processes.

9 July 2024 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DLDawid Lipski
Dawid Lipski
ARArtur Radziemski
Artur Radziemski
SWStanisław Wasiliew
Stanisław Wasiliew
MWMichał Wyrwa
Michał Wyrwa
LSLudwina Szczepaniak-Chicheł
Ludwina Szczepaniak-Chicheł
AKAnna Komosa
Anna Komosa
Background: Coronavirus disease (COVID-19) may lead to serious complications and increased mortality. The outcomes of patients who survive the early disease period are burdened with persistent long-term symptoms and increased long-term morbidity and mortality. The aim of our study was to determine which baseline parameters may provide the best prediction of early and long-term outcomes. Methods: The study group comprised 141 patients hospitalized for COVID-19. Demographic data, clinical data and laboratory parameters were collected. The main study endpoints were defined as in-hospital mortality and 1-year mortality. The associations between the baseline data and the study endpoints were evaluated. Prediction models were created. Results: The in-hospital mortality rate was 20.5% (n = 29). Compared with survivors, nonsurvivors were significantly older (p = 0.001) and presented comorbidities, including diabetes (0.027) and atrial fibrillation (p = 0.006). Assessment of baseline laboratory markers and time to early death revealed negative correlations between time to early death and higher IL-6 levels (p = 0.032; Spearman rho − 0.398) and lower lymphocyte counts (p = 0.018; Pearson r -0.438). The one-year mortality rate was 35.5% (n = 50). The 1-year nonsurvivor subgroup was older (p < 0.001) and had more patients with arterial hypertension (p = 0.009), diabetes (p = 0.023), atrial fibrillation (p = 0.046) and active malignancy (p = 0.024) than did the survivor subgroup. The model composed of diabetes and atrial fibrillation and IL-6 with lymphocyte count revealed the highest value for 1-year mortality risk prediction. Conclusions: Diabetes and atrial fibrillation, as clinical factors, and LDH, IL-6 and lymphocyte count, as laboratory determinants, are the best predictors of COVID-19 mortality risk.

10 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DLDawid Lipski
Dawid Lipski
DMDorota Marzyńska
Dorota Marzyńska
PSPaulina Sytek
Paulina Sytek
PRPatrycja Rzesoś
Patrycja Rzesoś
ARAgnieszka Rabiza
Agnieszka Rabiza
Paweł UruskiPaweł Uruski
Paweł Uruski
One of the causes of hypertension is excess weight gain, which can also affect the course of this disease. Both the diagnosis and management of hypertension commonly use ambulatory blood pressure monitoring; the results of which correlate more strongly with cardiovascular diseases and cardiovascular death than office blood pressure monitoring. We evaluated blood pressure values and their variability from hour to hour to see if and when they differed between hypertensive patients with and without obesity. The study included 1345 patients who underwent 24 h ambulatory blood pressure monitoring and then were divided into groups according to body mass index and waist circumference. The obtained data were analyzed according to the subjects’ wake-up time, and short-term blood pressure variability parameters were calculated as the mean of the absolute values of the differences between consecutive measurements. The systolic blood pressure in obese subjects was significantly higher between 1 and 5 h before waking than in normal-weighted individuals. In turn, the variability in systolic and diastolic blood pressure was higher with increasing body mass index. The difference in systolic blood pressure values and blood pressure variability was most prominent in the last 5 h of sleep in obese patients.

5 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
SNSonia Alicja Nartowicz
Sonia Alicja Nartowicz
LSLudwina Szczepaniak-Chicheł
Ludwina Szczepaniak-Chicheł
DLDawid Lipski
Dawid Lipski
IMIzabela Miechowicz
Izabela Miechowicz
ABAgnieszka Bartczak-Rutkowska
Agnieszka Bartczak-Rutkowska
OTOlga Trojnarska
Olga Trojnarska
Background and Aim: Patients with cyanosis secondary to congenital heart disease (CHD) are characterized by erythrocytosis and increased blood viscosity, which contribute to endothelial dysfunction, increased arterial stiffness, and impaired vascular function, which may affect the final clinical presentation. Asymmetric dimethylarginine (ADMA) and e-selectin (e-sel) are valuable biomarkers for endothelial and vascular dysfunction. Their concentration levels in blood serum have the potential to be an accessible tool that reflects the severity of the disease. We aimed to assess e-sel and ADMA levels and their relationship with the clinical status and endothelial and vascular function. Methods: A cross-sectional study, including 36 adult CHD cyanotic patients [(17 males) (42.3 ± 16.3 years)] with an arterial blood oxygen saturation less than 92% and 20 healthy controls [(10 males) (38.2 ± 8.5 years)], was performed. All the patients underwent a clinical examination, blood testing, and cardiopulmonary tests. Their endothelial function was assessed using the intima media thickness and flow-mediated dilatation. Vascular function, using applanation tonometry methods, was determined using the aortic systolic pressure, aortic pulse pressure, augmentation pressure, augmentation index, pulse pressure amplification, and pulse wave velocity. Results: The concentrations of e-sel and ADMA were significantly higher in the patients with CHD. The E-sel levels correlated positively with red blood cells, hemoglobin concentration, hematocrit, and augmentation pressure; they correlated negatively with blood oxygen saturation, the forced expiratory one-second volume, forced vital capacity, and oxygen uptake. The ADMA levels were found to correlate only with age. Conclusions: The E-sel level, unlike ADMA concentration, reflects the severity of erythrocytosis and hypoxia and, thus, the physical status of patients with cyanotic CHD.

23 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LSLudwina Szczepaniak-Chicheł
Ludwina Szczepaniak-Chicheł
DLDawid Lipski
Dawid Lipski
Paweł UruskiPaweł Uruski
Paweł Uruski
ATAndrzej Tykarski
Andrzej Tykarski
Background/Objectives: Central hemodynamic assessment may provide information complementary to brachial blood pressure in hypertensive disorders of pregnancy, but its clinical predictive value remains uncertain. This prospective longitudinal study evaluated central aortic systolic blood pressure (AoSBP), augmentation index (AIx), augmentation index normalized to 75 beats/min (AIxHR75), pulse pressure amplification (PPAmpl), and carotid–femoral pulse wave velocity (cfPWV) in pregnant women followed at a tertiary outpatient clinic in Poznan, Poland. Methods: Between 2017 and 2023, 241 consecutive pregnant women were examined during pregnancy and postpartum using applanation tonometry (SphygmoCor® PVx). The cohort included 40 normotensive controls, 152 women with hypertension without preeclampsia (HT), and 49 women with hypertension complicated by preeclampsia (HT + PE). Longitudinal profiles were analyzed using prespecified gestational periods, and additional mixed-effects and exploratory ROC analyses were performed in the subgroup with complete observations from 19–22 to 31–34 weeks of gestation. Results: AoSBP was consistently lower in controls than in hypertensive women despite pharmacological control of brachial blood pressure in the hypertensive groups. In the complete-case analysis, AoSBP differentiated the groups most clearly: it was higher in HT than in controls from 19–22 to 31–34 weeks and increased further in HT + PE from 23–26 weeks onward. PPAmpl showed no significant group, period, or interaction effect, whereas AIx and AIxHR75 changed over time but did not show robust between-group differences after Holm correction. Exploratory ROC analyses showed only moderate discrimination for selected parameters and should be considered hypothesis-generating. Conclusions: Women who developed preeclampsia showed an altered central hemodynamic phenotype compared with normotensive pregnancies and uncomplicated hypertensive pregnancies. These findings indicate association and discrimination at the group level, not clinically validated early prediction. External validation and multivariable models including conventional clinical variables and blood pressure measures are required before clinical implementation.

28 November 2025 in Artery Research
Verified
Journal Article
Open access
PDF file
SWStanislaw Wasiliew
Stanislaw Wasiliew
DLDawid Lipski
Dawid Lipski
LSLukasz Stryczynski
Lukasz Stryczynski
ARArtur Radziemski
Artur Radziemski
JKJan Królak
Jan Królak
Paweł UruskiPaweł Uruski
Paweł Uruski
Background: Resistant hypertension affects 10–15% of treated patients and remains a therapeutic challenge. Eplerenone is recommended when spironolactone is ineffective or poorly tolerated. Central blood pressure (BP) correlates more strongly with cardiovascular complications than peripheral BP, and pulse wave velocity (PWV) reflects arterial stiffness, a key factor in hypertension-related morbidity. While spironolactone is well-established for resistant hypertension, data on eplerenone’s efficacy and safety for this indication is limited. Interleukin-6 (IL-6) is involved in resistant hypertension and the pressor response to angiotensin II, with elevated levels suggesting its role in aldosterone regulation and potential as a therapeutic target. This study aimed to evaluate the efficacy of eplerenone (25–50 mg/day) on central aortic BP, PWV, office BP, ambulatory BP monitoring (ABPM), and IL-6 levels after four weeks. Twenty-seven patients with confirmed resistant hypertension received eplerenone for four weeks. Office BP, ABPM, central aortic BP, PWV, and safety markers (potassium, creatinine) were measured. IL-6 levels were assessed at baseline and post-treatment. Results: Significant reductions were observed in office BP (SBP: −13.93 mmHg, DBP: −7.64 mmHg), aortic BP (SBP: −13.42 mmHg, DBP: −7.94 mmHg), 24 h-ABPM (SBP: −7 mmHg, DBP: −3 mmHg), and PWV (− 1.52 m/s). Doubling the eplerenone dose from 25 mg to 50 mg daily reduces aortic systolic blood pressure threefold. IL-6 levels also decreased significantly ( p = 0.023). Conclusions: Eplerenone effectively reduces central and peripheral BP, arterial stiffness, and IL-6 levels, potentially lowering cardiovascular risk in resistant hypertension.